Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

715
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
715
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

1.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial Alterations and CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Round and round we go: phosphoenolpyruvate carboxykinase 1 (PCK1) in cataplerosis, mitochondrial, and kidney health.

Kidney international·2025
Same author

Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes.

Oncoimmunology·2025
Same author

Human proximal tubular epithelial cell interleukin-1 receptor signalling triggers G2/M arrest and cellular senescence during hypoxic kidney injury.

Cell death & disease·2025
Same author

Association between enteral carboxymethyllysine intake and daily glycemic variability in critically ill adults: A retrospective cohort study.

JPEN. Journal of parenteral and enteral nutrition·2025
Same author

Kidney Hyperfiltration and Mitochondrial Changes Are Associated With eGFR Decline in Young People With Type 1 Diabetes.

The Journal of clinical endocrinology and metabolism·2024

Related Experiment Video

Updated: Sep 19, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K

Type 1 diabetes mellitus prevention: present and future.

Francisca L Henriques1, Irina Buckle1,2, Josephine M Forbes3,4,5

  • 1Diabetes and Metabolism Laboratory, Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.

Nature Reviews. Endocrinology
|June 17, 2025
PubMed
Summary
This summary is machine-generated.

Preventing Type 1 diabetes (T1DM) is crucial due to rising incidence and mortality. This review explores teplizumab and novel strategies like targeting the receptor for advanced glycation end products (RAGE) for T1DM prevention.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K
Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Related Experiment Videos

Last Updated: Sep 19, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K
Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Area of Science:

  • Immunology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Type 1 diabetes mellitus (T1DM) is a growing global health concern with significant mortality from its complications.
  • Historically viewed as T cell-mediated, T1DM pathogenesis now includes the active role of beta-cells in immune-mediated damage.
  • Beta-cell heterogeneity, stress vulnerability, and antigen-presenting capabilities necessitate new prevention and preservation strategies.

Purpose of the Study:

  • To review current and potential therapeutic strategies for preventing Type 1 diabetes mellitus.
  • To explore alternative approaches beyond T cell-targeted therapies.
  • To highlight the potential of targeting the receptor for advanced glycation end products (RAGE) in T1DM prevention.

Main Methods:

  • Review of existing literature on T1DM prevention therapies.
  • Analysis of the role of beta-cells in T1DM pathogenesis.
  • Exploration of novel therapeutic targets, including RAGE.

Main Results:

  • Teplizumab is the only FDA-approved therapy for delaying T1DM onset, but faces challenges in administration and side effects.
  • Understanding beta-cell roles offers new avenues for therapeutic intervention.
  • Targeting RAGE presents a promising alternative approach for T1DM prevention.

Conclusions:

  • Effective T1DM prevention requires a multifaceted approach considering both immune and beta-cell aspects.
  • While teplizumab offers a pathway, challenges remain for widespread clinical adoption.
  • Targeting RAGE and related pathways holds significant potential for future T1DM prevention therapies.